Ravi Kiron
Consultant / Advisor presso ShangPharma Innovation, Inc.
Profilo
Ravi Kiron is the founder of C2N Diagnostics LLC, which was founded in 2007.
He held the title of Chief Business Officer from 2007 to 2008.
Dr. Kiron's current jobs include Head & BioPharma External Innovation at EMD Serono, Inc. since 2017, and Executive-in-Residence at ShangPharma Innovation, Inc. since 2017.
Dr. Kiron's former jobs include Executive Director at Johnson & Johnson from 2004 to 2007, Managing Director at Adjuvant Partners LLC from 2008 to 2011, and Global Head, Strategic Analysis & KM at Pfizer Inc. from 1991 to 2004.
He also served as Chief Business Officer at KineMed, Inc. and as a Business Development Advisor at Aduro BioTech, Inc. from 2010 to 2012.
Dr. Kiron's education includes an MBA from Rensselaer Polytechnic Institute in 1998, a doctorate from the Indian Institute of Science in 1986, and undergraduate and graduate degrees from the University of Mumbai in 1979 and 1981 respectively.
Posizioni attive di Ravi Kiron
Società | Posizione | Inizio |
---|---|---|
ShangPharma Innovation, Inc.
ShangPharma Innovation, Inc. Investment ManagersFinance ShangPharma Innovation Inc. (ShangPharma Innovation) is a venture capital firm, a subsidiary of Shangpharma Investment Group Ltd. founded in 2016. The firm is headquartered in San Francisco, California. | Consultant / Advisor | 01/02/2017 |
EMD Serono, Inc.
EMD Serono, Inc. Pharmaceuticals: MajorHealth Technology EMD Serono, Inc. operates as a biopharmaceutical firm. The firm develops recombinant prescription medicines. Its therapies include neurology and immunology, metabolic endocrinology, fertility, and oncology. The company was founded in 1971 and is headquartered in Rockland, MA. | Corporate Officer/Principal | 01/06/2017 |
Precedenti posizioni note di Ravi Kiron
Società | Posizione | Fine |
---|---|---|
CHINOOK THERAPEUTICS, INC. | Consultant / Advisor | 01/04/2012 |
Adjuvant Partners LLC | Corporate Officer/Principal | 01/01/2011 |
C2N Diagnostics LLC
C2N Diagnostics LLC BiotechnologyHealth Technology C2N Diagnostics LLC is a private company that focuses on mechanism-based approaches to prevent or stop the progression of human neurological disorders. The company is based in St. Louis, MO. The company's lead commercial product, PrecivityAD™, is a mass spectrometry-based test that measures in blood multiple analytes including a?42, a?40, and apolipoprotein e isoforms. This test predicts brain amyloid plaques as determined by PET scan results and received a breakthrough device designation from the Food and Drug Administration in early 2019. C2N Diagnostics aims to bring accurate, widely accessible, and cost-effective blood tests to the clinic for the betterment of patient care and brain health monitoring in the field of neurodegeneration and Alzheimer's disease. The company was founded by Ravi Kiron, Joel Bennett Braunstein, Ilana Fogelman. Joel Bennett Braunstein has been the CEO since incorporation. | Founder | 01/07/2008 |
JOHNSON & JOHNSON | Corporate Officer/Principal | 01/01/2007 |
PFIZER, INC. | Corporate Officer/Principal | 01/01/2004 |
Formazione di Ravi Kiron
Rensselaer Polytechnic Institute | Masters Business Admin |
Indian Institute of Science | Doctorate Degree |
University of Mumbai | Graduate Degree |
Esperienze
Posizioni ricoperte
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 2 |
---|---|
JOHNSON & JOHNSON | Health Technology |
PFIZER, INC. | Health Technology |
Aziende private | 6 |
---|---|
KineMed, Inc.
KineMed, Inc. Miscellaneous Commercial ServicesCommercial Services KineMed, Inc. develops and commercializes biomarker platform technology. It provides dynamic proteomics platform, a functionally interpretable systems biology platform. The company was founded by David M. Fineman and Marc K. Hellerstein in February 2001 and is headquartered in Emeryville, CA. | Commercial Services |
Aduro BioTech, Inc.
Aduro BioTech, Inc. Pharmaceuticals: MajorHealth Technology Aduro BioTech, Inc. is a clinical-stage immunotherapy company, which engages in the discovery, development, and commercialization of therapies that transform the treatment of diseases, including cancer. Its technology platforms include STING Pathway Activator, B-select monoclonal antibody, and LADD, or Live, Attenuated, Double-Deleted Listeria monocytogenes. The company's platforms stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies like chemotherapy and radiation as well as other novel immunotherapies. Aduro BioTech was founded in 2000 and is headquartered in Berkeley, CA. | Health Technology |
EMD Serono, Inc.
EMD Serono, Inc. Pharmaceuticals: MajorHealth Technology EMD Serono, Inc. operates as a biopharmaceutical firm. The firm develops recombinant prescription medicines. Its therapies include neurology and immunology, metabolic endocrinology, fertility, and oncology. The company was founded in 1971 and is headquartered in Rockland, MA. | Health Technology |
C2N Diagnostics LLC
C2N Diagnostics LLC BiotechnologyHealth Technology C2N Diagnostics LLC is a private company that focuses on mechanism-based approaches to prevent or stop the progression of human neurological disorders. The company is based in St. Louis, MO. The company's lead commercial product, PrecivityAD™, is a mass spectrometry-based test that measures in blood multiple analytes including a?42, a?40, and apolipoprotein e isoforms. This test predicts brain amyloid plaques as determined by PET scan results and received a breakthrough device designation from the Food and Drug Administration in early 2019. C2N Diagnostics aims to bring accurate, widely accessible, and cost-effective blood tests to the clinic for the betterment of patient care and brain health monitoring in the field of neurodegeneration and Alzheimer's disease. The company was founded by Ravi Kiron, Joel Bennett Braunstein, Ilana Fogelman. Joel Bennett Braunstein has been the CEO since incorporation. | Health Technology |
ShangPharma Innovation, Inc.
ShangPharma Innovation, Inc. Investment ManagersFinance ShangPharma Innovation Inc. (ShangPharma Innovation) is a venture capital firm, a subsidiary of Shangpharma Investment Group Ltd. founded in 2016. The firm is headquartered in San Francisco, California. | Finance |
Adjuvant Partners LLC |
- Borsa valori
- Insiders
- Ravi Kiron